The Zhitong Finance App learned that Braveheart Bio Inc., a clinical-stage biopharmaceutical company supported by A16z, submitted an IPO application to NASDAQ on Wednesday.

The cardiovascular drug developer will seek to raise an undisclosed amount of capital by selling shares on the NASDAQ Global Marketplace. The company's main drug candidate is BHB-1893, which is currently being developed to treat hypertrophic cardiomyopathy.

To date, the company has raised $185 million from investors including a16z's biotech fund and Patient Square Capital. Christopher Weibach, CEO of BIIB.US, is the chairman of Braveheart.

Braveheart reports that in the first three months of 2026, it had a net loss of $14.3 million and generated approximately $11 million in revenue. In comparison, the net loss for the first three months of the same period last year was $9.9 million.

Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor are acting as co-underwriters for this launch. Braveheart will trade under the ticker “BRVE.”

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.